August 12, 2025 • 17 mins
Digital companions are revolutionizing the post-prescription landscape, turning traditional patient support upside down. Cathy Zaremba, Senior Director of Marketing at Medisafe, reveals how personalized, data-driven platforms are transforming medication adherence and patient outcomes through just-in-time interventions.
The statistics are sobering: only 50% of patients with chronic conditions adhere to treatments long-term, costing the US healthcare system an estimated $300 billion annually. Meanwhile, 71% of patients crave digital experiences that align with their personal habits. Medisafe addresses this gap with sophisticated technology that meets patients exactly where they are in their therapeutic journey.
What makes digital companions effective isn't just technology—it's empathy. "Information alone doesn't change behavior," Zaremba explains. Through intelligent design and personalized support, Medisafe users stay engaged for an average of 17 months (compared to typical 30-day drop-offs), with 70% interacting at least once daily. Simple empathetic language has shown to improve engagement by over 40% during challenging therapy points, proving that patients "aren't just engaging with tech, they're engaging with trust."
The conversation explores Medisafe's exciting innovations, including Via—their voice intelligent agent combining conversational AI with behavioral data to create natural, supportive interactions. Zaremba also shares how Medisafe captures over 50 billion data points globally, providing pharma companies with unprecedented visibility into patient behavior patterns that were previously invisible through traditional reporting.
As healthcare continues evolving toward value-based care, Medisafe is expanding AI-powered predictive adherence tools and integrations across health ecosystems. The message is clear: the future of patient support isn't just about prescriptions written—it's about prescriptions completed and lives improved.
Listen now to discover how digital companions are becoming the critical difference-maker in patient success stories worldwide. Follow Postscript for more insights at the intersection of pharma, technology, and patient impact.
PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
One second.
Hello and welcome to Postscript, the podcast exploring what
happens after the firstprescription.
We cover the latest innovationsin patient access, support,
(00:21):
digital tools, hcp engagementand pharma marketing that drive,
hopefully, better outcomes forpatients.
This podcast is forinformational purposes only and
does not constitute medicaladvice or should influence any
clinical decision-making.
Patients should always consulttheir healthcare professionals.
Welcome to the podcast.
My name is Brian Carr and I'mthe Senior Vice President of
(00:42):
Medisafe, although any opinionsexpressed here are my own and
that of my guests, and notnecessarily those of Medisafe,
its partners or the guests'partners as well.
So let me, without any furtherdelay, introduce our guest,
kathy Zaremba of Medisafe.
Hello, kathy.
Speaker 2 (00:58):
Hello Brian, Thanks for having me.
Speaker 1 (01:00):
Of course.
Of course, good seeing youagain.
And Kathy is a key voice atMedisafe and, you know, a
driving force behind digitaltherapeutic engagement.
She brings forth an inside lookon how digital health tools are
transforming how the lifesciences industry connects with,
supports and retains patients,from lowering drop-off risk to
(01:21):
building omni-channelexperiences that actually fit
into patients' lives.
So, with pharma brands and lifescience companies under
pressure to do more, withtighter budgets, rising
expectations for patientengagement and a complex
post-launch commercializationlandscape, digital, when
executed well, is now becoming amake-or-break factor for many,
many teams.
(01:41):
So why do digital companionsmatter?
Now, before we get intoquestions with Kathy, let's just
set ground ourselves in some ofthe why behind why we're
talking today.
You know, when we think oftraditional patient support
models, they've often reliedheavily on call centers and
paper enrollment forms andreactive support solutions.
(02:02):
However, research has shownthat you know these legacy
models are no longer efficient.
Consider that only 50% ofpatients adhere to chronic
condition treatments over thelong term, and you know that's a
gap costing the US healthcaresystem an estimated $300 billion
or more annually.
And that's from the CDC.
A McKinsey report recentlyfound that digital health
(02:22):
engagement can improvemedication adherence by 15% to
30% and reduce abandonment ofspecialty medications
pre-initiation by up to 22%.
So patients, too, also nowexpect personalization from
their digital tools 71% say theywant digital experiences that
align with their personal habitsand routines.
(02:45):
That's according to anAccenture health and life survey
last year.
So enter the Medisave DigitalCompanion, a personalized,
seamless, integrated platformthat adapts to each patient's
individual journey.
So let's shift our attention towhat pharma innovators,
marketers, access leaders wantto hear from Kathy.
(03:06):
Here's some of the questionswe're going to explore.
Kathy, let's start.
Not everyone listening mayfully grasp how Medisafe
operates behind the scenes, incollaboration with pharma or in
life science companies, so we'dlove to understand your unique
role at the heart of theecosystem.
So tell us about your rolewithin the company.
Speaker 2 (03:24):
Sure, yeah, and I'd love to explore what our
Medisafe mission is too.
So at Medisafe, our mission issimple but powerful.
We help patients succeed withtheir treatment every single day
.
We believe that if you givepatients the right support at
the right time, thatpersonalized to their needs,
you're going to improve not justtheir adherence but also the
(03:46):
quality of life and the healthoutcomes.
So here at MetaSafe, as SeniorDirector of Marketing, my role
is to bridge product innovationwith real-world pharma needs.
I work closely with ourcommercial team, our product
development teams and alsodirectly with pharma partners,
and we understand what the brandstrategies are and how to shape
(04:06):
digital companion experiencesthat are, at the heart of it,
patient-centric and alsobrand-aligned.
So we're really operating as atrue digital partner, not just a
vendor, and we want to help ourpharma partners maximize
adherence, engagement anddata-driven insights across the
whole therapeutic lifecycle.
Speaker 1 (04:28):
Okay, great.
Can you further define what isa Medisave digital companion and
how that might get used bypharma brands today?
Speaker 2 (04:36):
Yeah, sure, sure.
So.
At Medisave, our digitalcompanion is a personalized
data-driven platform that walksright alongside patients
throughout their therapy journey, and so, unlike a static
reminder tool, our digitalcompanion adapts in real time,
and we call that our JITItechnology, or just-in-time
interventions, where we'redelivering the right message,
(04:58):
the right resource or action atexactly the point where it's
going to be the most impactfulfor patients and for pharma
brands.
What that means is it's notjust a tool for reminders, but
it's actually an integrated partof the patient journey.
It supports onboarding, helpsnavigate patient symptoms,
reinforces their confidenceactually in the therapy, and it
even connects them to financialassistance, if that's something
(05:21):
that they need.
Because it's also interoperable, it can complement the hub
services and also connect withnurse navigator programs, crm
systems and all of those typesof things, without adding
complexity.
Speaker 1 (05:36):
Got it.
And it goes beyond thecompanion too, because one of
your new innovations I readabout is Medisafe Via.
So what is that and how does itelevate that patient experience
?
You think even further.
Speaker 2 (05:48):
Yeah, I'm so glad you're asking and it is an
exciting new innovation thatwe've just launched in the
market.
So Via is our voice intelligentagent and it is our leap
forward into patient interaction.
It's going to combineconversational AI, voice
technology and data signals tocreate a truly personalized and
(06:08):
natural feeling experience.
So, instead of someone havingto just scroll through menus or
click buttons, a patient canjust ask hey, when is my next
dose or what should I do aboutthis symptom, and then they're
going to get really relevantsupport right at that moment.
We have seen this reducebarriers for patients and it's
(06:29):
also creating that sense ofconnection that's human, even
though it's powered through AI.
Speaker 1 (06:37):
Got it and I'm going to put a link in the show notes
to MetaSavvy where people cantake a look and hear some calls
from themselves.
It's interesting because it isan automated voice agent, what
we would call AI, and I thinkwhat first people are going to
say well, I don't want to talkto a robot, right, but I
guarantee you a year from now,when you're on the phone with
someone and they say hello,you've contacted X company,
(06:58):
insurance company or whatever,and you're 25th in the queue, so
we'll get to you.
You know people going or youcan talk to someone right now.
That's a voice agent.
The people go yeah, I'll talkto that, let's just go right.
Speaker 2 (07:08):
Exactly, exactly.
Speaker 1 (07:10):
Yeah, so what do you think you've learned about?
You know behavior design anddigital therapeutics that pharma
teams may underestimate,especially what Medisafe has
such scale that pharma teams mayunderestimate, especially when
Medisafe has such scale.
Speaker 2 (07:26):
Uh-huh, uh-huh.
This is fascinating andactually one of our big lessons
is that information alonedoesn't change behavior.
So you have to motivate, youhave to build confidence, and
timing also matters.
So a lot of times pharmadigital tools they front load
education at the point ofinitiation, but it doesn't keep
them engaged after the first fewweeks.
So behavior design means thatthinking about the patient
journey, we're thinking aboutthat in terms of, like, micro
(07:49):
moments and understanding.
When does the patient feel alittle uncertain, when do they
need a little boost ofencouragement and when are they
at their most receptive momentfor action, to take action on
what's happening?
So digital therapeutics arereally going to be successful
when they're able tocontinuously adapt rather than
(08:10):
just taking thisone-size-fits-all approach.
Speaker 1 (08:13):
Yeah, and I could see where that would work on a new
script.
Someone just got prescribed andthey're just starting out, or
they may have forgotten whenthey were shown how to inject
themselves at the hospitalbefore they were discharged.
Right, sometimes you'll getthat.
But so how does Medisafesupport patients through their
entire therapeutic life cycle,not just at the beginning?
Speaker 2 (08:31):
Yeah, that's such a great point because it's all
about the entire and the totaljourney, not just one particular
moment in time.
So we definitely support acrossthe entire life cycle.
So, when you think aboutpre-initiation, what we want to
do is be able to delivereducational content to sort of
set those expectations, addressany fears they may have about
(08:51):
therapy or how it's going to beadministered, and smooth that
onboarding process.
So that's at the pre-initiationstage, early in the life cycle,
of them addressing and being ontherapy, we're able to provide
that proactive guidance andencouragement to prevent early
drop-off from therapy, reinforcethose positive routines, help
(09:18):
them manage different symptomsthat they may be experiencing
and surface those jitty moments,those timely nudges.
We can even address access andaffordability, where we're going
to connect patients tofinancial assistance if that's
something that they need.
And this holistic 360 view ofthe journey is what keeps
patients on therapy longer andfor us it's actually why the
(09:42):
average Medisafe user stickswith Medisafe over 17 months,
compared to most apps wherethere's a drop-off within the
first 30 days.
Speaker 1 (09:51):
Yeah, it's interesting because I've seen
also data where, even if theyfor some reason weren't using
Medisafe because they've beendoing it for three years, they
haven't uninstalled it fromtheir phone.
And we've asked them why?
Well, because if I somehow falloff my treatment or I forget, I
want to make sure it's thereand get me right back on track
again.
It's really interesting.
Speaker 2 (10:08):
So yeah, yeah, well, and our engagement is through
the roof.
I mean, 70% of our patients areactually interacting at least
once a day, so you have tocreate that sticky experience
Right.
So how does Medisafe solve foradherence?
That's a great question.
(10:32):
We really view this as how doyou combine personalization with
that jitty real-timeintervention experience?
And it's not enough to justtell somebody what to do.
We help them to overcome thewhy not?
And so, for example, when apatient has a therapy question,
we can immediately triggereducational content or connect
them to a nurse navigator andreally reduce that risk that
they'll abandon therapy.
(10:52):
Across multiple brands, we'veseen double-digit increases in
persistent rates, sometimesextending time on therapy by
several months, which is, hey, awin for both the patients and
the brands.
Speaker 1 (11:06):
Gotcha, and if I'm on a brand team, I can get my
weekly and monthly reports,maybe even quarterly, on.
Here's the new RXs that werefilled in my region this week,
this month, this period.
Here's the refills that weredone.
But you but?
Is there other data insightsMedisafe is delivering back to
pharma teams that, frankly, theypreviously were invisible to in
regular models?
Speaker 2 (11:29):
It's incredible when you think about all of the data
that we are capturing literallyover 50 billion data points that
we're collecting on all ofthese patients globally we
really are able to give pharmainsights that they have never
seen before.
So we're not just tracking if adose was taken, we're actually
capturing why a dose might bemissed, or when engagement's
(11:52):
going to drop off and whatinterventions actually are
effective in re-engagingpatients.
So you know, for example, wecan see patterns like patients
tend to disengage around day 17if they've experienced certain
symptoms.
Well, that insight triggers ourJITI engine to preemptively
send targeted support at thatexact point in the patient's
(12:13):
journey.
And that's the kind ofbehavioral intelligence that is
just not available if you'relooking at claims data or
traditional hub reporting.
Speaker 1 (12:23):
So if I'm a patient listening to this, I might be a
little concerned about privacy.
How does Medisave handle myprivate data if we're sending it
to pharma companies?
Speaker 2 (12:31):
Well, privacy is paramount, and so we absolutely.
It is a consent-based situation.
Patients opt in to participatein the first place.
It's their data, they own theirdata.
We are HIPAA compliant, we areGDPR compliant, so we really
elevate and make sure that weare keeping patients' data
(12:52):
secure.
Speaker 1 (12:54):
And what surprised you the most.
In what patients are tellingyou about, you know what they
value the most in their digitalsupport tools.
Speaker 2 (13:01):
Oh, the biggest surprise.
Honestly, I think that patientsare more emotionally invested
than we really think, so weassume that they would want pure
utility.
But what we hear a lot is thatthis makes me feel seen, this
makes me feel heard.
We hear from patients regularly.
We have so many app storereviews where they're saying
(13:23):
MetaSafe really saved my life.
This is really bringingpatients through their ups and
downs and not just pushingalerts at them.
So you know, for example, we'vedone A-B testing and we've
shown that simple empatheticlanguage like we know it's hard,
and we've shown that simpleempathetic language, like we
know it's hard, but you've gotthis has improved engagement by
over 40% during challengingtherapy points.
(13:46):
So we're really addressing thiswhen they're facing the biggest
challenges.
And patients aren't justengaging with tech, they are
engaging with trust, and that'sshaped our design principles
going forward, and caregivers aswell, because sometimes they
can add a friend or somethingright.
Yeah, that friend very effective.
We've seen that that actuallyhas a huge contribution to
(14:08):
patient adherence, just knowingthat they've got someone walking
alongside them in that journey.
Speaker 1 (14:13):
All right.
So collaboration is often wherethe biggest digital health
challenges lie right.
So how does Medisave partnerwith pharma and life science
companies, versus just trying tosell a solution?
Speaker 2 (14:26):
Yeah, you know this goes back to we are not just a
vendor, we consider ourselvespharma's partner.
So in that way, what makes usdifferent is we are really
integrated within the pharmateams.
So we go and conduct pre-launchworkshops, we really align to
their launch objectives, wetrain the field so that across
(14:49):
commercial teams, across the ITand security cross-access teams
(15:09):
and with this we are ensuringthat there is internal alignment
and external adoption, becausedigital success comes from
really connecting that ecosystemand not just doing it in a silo
.
Speaker 1 (15:24):
Great.
And my last question, asdigital health rapidly is
evolving here and ever-changing,where do you see Medisafe
heading over the next two tothree years?
Speaker 2 (15:47):
So Medisafe over the next two to three years, that is
really we are adapting andreally doubling down on our AI
interventions.
We are really looking forwardto where can we layer this in
across multiple healthecosystems?
So we're advancing AIintegrations for predictive
adherence.
We are expanding into otherintegrations like EHR systems,
pharmacy services and thingslike that, and, of course, we're
global.
So we are global in every wayand we're making sure that we
(16:10):
are adaptive to all of the needs.
We have SDK modules that we'reable to integrate with.
So pharma, their needs arereally evolving I'd say rapidly
and they are being confrontedwith value-based care.
And how do they handle that?
What's a digital-firstintervention that's going to
work and really deliver on thatpatient ROI?
(16:31):
So we are ready Medisafe isready to scale across this with
handling and dealing with thecomplexities, while still
staying grounded in our roots ofempathy, evidence and
engagement.
Speaker 1 (16:47):
Thanks so much, kathy , for joining us today.
What you and the Medisave teamare really building represents
this new blueprint for howpharma and life sciences can
really move from justtransactions to trusted
relationships.
And you know, the real metricisn't just prescriptions written
, it's really prescriptionscompleted.
You know we're improving livesand you know we're moving
barriers and really helpingpeople on their journey.
(17:09):
So thank you so much forjoining us today.
On Postscripts A pleasure to behere, brian.
Thank you All.
Right, everyone.
If you found this conversationvaluable, follow or subscribe
for more insights at theintersection of pharma, tech and
patient impact.
Until next time, keep lookingforward.
The real work begins after thescript is written.
Have a good day everybody.
One second.
Hello and welcome to Postscript, the podcast exploring what
happens after the firstprescription.
We cover the latest innovationsin patient access, support,
(00:21):
digital tools, hcp engagementand pharma marketing that drive,
hopefully, better outcomes forpatients.
This podcast is forinformational purposes only and
does not constitute medicaladvice or should influence any
clinical decision-making.
Patients should always consulttheir healthcare professionals.
Welcome to the podcast.
My name is Brian Carr and I'mthe Senior Vice President of
(00:42):
Medisafe, although any opinionsexpressed here are my own and
that of my guests, and notnecessarily those of Medisafe,
its partners or the guests'partners as well.
So let me, without any furtherdelay, introduce our guest,
kathy Zaremba of Medisafe.
Hello, kathy.
Speaker 2 (00:58):
Hello Brian, Thanks for having me.
Speaker 1 (01:00):
Of course.
Of course, good seeing youagain.
And Kathy is a key voice atMedisafe and, you know, a
driving force behind digitaltherapeutic engagement.
She brings forth an inside lookon how digital health tools are
transforming how the lifesciences industry connects with,
supports and retains patients,from lowering drop-off risk to
(01:21):
building omni-channelexperiences that actually fit
into patients' lives.
So, with pharma brands and lifescience companies under
pressure to do more, withtighter budgets, rising
expectations for patientengagement and a complex
post-launch commercializationlandscape, digital, when
executed well, is now becoming amake-or-break factor for many,
many teams.
(01:41):
So why do digital companionsmatter?
Now, before we get intoquestions with Kathy, let's just
set ground ourselves in some ofthe why behind why we're
talking today.
You know, when we think oftraditional patient support
models, they've often reliedheavily on call centers and
paper enrollment forms andreactive support solutions.
(02:02):
However, research has shownthat you know these legacy
models are no longer efficient.
Consider that only 50% ofpatients adhere to chronic
condition treatments over thelong term, and you know that's a
gap costing the US healthcaresystem an estimated $300 billion
or more annually.
And that's from the CDC.
A McKinsey report recentlyfound that digital health
(02:22):
engagement can improvemedication adherence by 15% to
30% and reduce abandonment ofspecialty medications
pre-initiation by up to 22%.
So patients, too, also nowexpect personalization from
their digital tools 71% say theywant digital experiences that
align with their personal habitsand routines.
(02:45):
That's according to anAccenture health and life survey
last year.
So enter the Medisave DigitalCompanion, a personalized,
seamless, integrated platformthat adapts to each patient's
individual journey.
So let's shift our attention towhat pharma innovators,
marketers, access leaders wantto hear from Kathy.
(03:06):
Here's some of the questionswe're going to explore.
Kathy, let's start.
Not everyone listening mayfully grasp how Medisafe
operates behind the scenes, incollaboration with pharma or in
life science companies, so we'dlove to understand your unique
role at the heart of theecosystem.
So tell us about your rolewithin the company.
Speaker 2 (03:24):
Sure, yeah, and I'd love to explore what our
Medisafe mission is too.
So at Medisafe, our mission issimple but powerful.
We help patients succeed withtheir treatment every single day
.
We believe that if you givepatients the right support at
the right time, thatpersonalized to their needs,
you're going to improve not justtheir adherence but also the
(03:46):
quality of life and the healthoutcomes.
So here at MetaSafe, as SeniorDirector of Marketing, my role
is to bridge product innovationwith real-world pharma needs.
I work closely with ourcommercial team, our product
development teams and alsodirectly with pharma partners,
and we understand what the brandstrategies are and how to shape
(04:06):
digital companion experiencesthat are, at the heart of it,
patient-centric and alsobrand-aligned.
So we're really operating as atrue digital partner, not just a
vendor, and we want to help ourpharma partners maximize
adherence, engagement anddata-driven insights across the
whole therapeutic lifecycle.
Speaker 1 (04:28):
Okay, great.
Can you further define what isa Medisave digital companion and
how that might get used bypharma brands today?
Speaker 2 (04:36):
Yeah, sure, sure.
So.
At Medisave, our digitalcompanion is a personalized
data-driven platform that walksright alongside patients
throughout their therapy journey, and so, unlike a static
reminder tool, our digitalcompanion adapts in real time,
and we call that our JITItechnology, or just-in-time
interventions, where we'redelivering the right message,
(04:58):
the right resource or action atexactly the point where it's
going to be the most impactfulfor patients and for pharma
brands.
What that means is it's notjust a tool for reminders, but
it's actually an integrated partof the patient journey.
It supports onboarding, helpsnavigate patient symptoms,
reinforces their confidenceactually in the therapy, and it
even connects them to financialassistance, if that's something
(05:21):
that they need.
Because it's also interoperable, it can complement the hub
services and also connect withnurse navigator programs, crm
systems and all of those typesof things, without adding
complexity.
Speaker 1 (05:36):
Got it.
And it goes beyond thecompanion too, because one of
your new innovations I readabout is Medisafe Via.
So what is that and how does itelevate that patient experience
?
You think even further.
Speaker 2 (05:48):
Yeah, I'm so glad you're asking and it is an
exciting new innovation thatwe've just launched in the
market.
So Via is our voice intelligentagent and it is our leap
forward into patient interaction.
It's going to combineconversational AI, voice
technology and data signals tocreate a truly personalized and
(06:08):
natural feeling experience.
So, instead of someone havingto just scroll through menus or
click buttons, a patient canjust ask hey, when is my next
dose or what should I do aboutthis symptom, and then they're
going to get really relevantsupport right at that moment.
We have seen this reducebarriers for patients and it's
(06:29):
also creating that sense ofconnection that's human, even
though it's powered through AI.
Speaker 1 (06:37):
Got it and I'm going to put a link in the show notes
to MetaSavvy where people cantake a look and hear some calls
from themselves.
It's interesting because it isan automated voice agent, what
we would call AI, and I thinkwhat first people are going to
say well, I don't want to talkto a robot, right, but I
guarantee you a year from now,when you're on the phone with
someone and they say hello,you've contacted X company,
(06:58):
insurance company or whatever,and you're 25th in the queue, so
we'll get to you.
You know people going or youcan talk to someone right now.
That's a voice agent.
The people go yeah, I'll talkto that, let's just go right.
Speaker 2 (07:08):
Exactly, exactly.
Speaker 1 (07:10):
Yeah, so what do you think you've learned about?
You know behavior design anddigital therapeutics that pharma
teams may underestimate,especially what Medisafe has
such scale that pharma teams mayunderestimate, especially when
Medisafe has such scale.
Speaker 2 (07:26):
Uh-huh, uh-huh.
This is fascinating andactually one of our big lessons
is that information alonedoesn't change behavior.
So you have to motivate, youhave to build confidence, and
timing also matters.
So a lot of times pharmadigital tools they front load
education at the point ofinitiation, but it doesn't keep
them engaged after the first fewweeks.
So behavior design means thatthinking about the patient
journey, we're thinking aboutthat in terms of, like, micro
(07:49):
moments and understanding.
When does the patient feel alittle uncertain, when do they
need a little boost ofencouragement and when are they
at their most receptive momentfor action, to take action on
what's happening?
So digital therapeutics arereally going to be successful
when they're able tocontinuously adapt rather than
(08:10):
just taking thisone-size-fits-all approach.
Speaker 1 (08:13):
Yeah, and I could see where that would work on a new
script.
Someone just got prescribed andthey're just starting out, or
they may have forgotten whenthey were shown how to inject
themselves at the hospitalbefore they were discharged.
Right, sometimes you'll getthat.
But so how does Medisafesupport patients through their
entire therapeutic life cycle,not just at the beginning?
Speaker 2 (08:31):
Yeah, that's such a great point because it's all
about the entire and the totaljourney, not just one particular
moment in time.
So we definitely support acrossthe entire life cycle.
So, when you think aboutpre-initiation, what we want to
do is be able to delivereducational content to sort of
set those expectations, addressany fears they may have about
(08:51):
therapy or how it's going to beadministered, and smooth that
onboarding process.
So that's at the pre-initiationstage, early in the life cycle,
of them addressing and being ontherapy, we're able to provide
that proactive guidance andencouragement to prevent early
drop-off from therapy, reinforcethose positive routines, help
(09:18):
them manage different symptomsthat they may be experiencing
and surface those jitty moments,those timely nudges.
We can even address access andaffordability, where we're going
to connect patients tofinancial assistance if that's
something that they need.
And this holistic 360 view ofthe journey is what keeps
patients on therapy longer andfor us it's actually why the
(09:42):
average Medisafe user stickswith Medisafe over 17 months,
compared to most apps wherethere's a drop-off within the
first 30 days.
Speaker 1 (09:51):
Yeah, it's interesting because I've seen
also data where, even if theyfor some reason weren't using
Medisafe because they've beendoing it for three years, they
haven't uninstalled it fromtheir phone.
And we've asked them why?
Well, because if I somehow falloff my treatment or I forget, I
want to make sure it's thereand get me right back on track
again.
It's really interesting.
Speaker 2 (10:08):
So yeah, yeah, well, and our engagement is through
the roof.
I mean, 70% of our patients areactually interacting at least
once a day, so you have tocreate that sticky experience
Right.
So how does Medisafe solve foradherence?
That's a great question.
(10:32):
We really view this as how doyou combine personalization with
that jitty real-timeintervention experience?
And it's not enough to justtell somebody what to do.
We help them to overcome thewhy not?
And so, for example, when apatient has a therapy question,
we can immediately triggereducational content or connect
them to a nurse navigator andreally reduce that risk that
they'll abandon therapy.
(10:52):
Across multiple brands, we'veseen double-digit increases in
persistent rates, sometimesextending time on therapy by
several months, which is, hey, awin for both the patients and
the brands.
Speaker 1 (11:06):
Gotcha, and if I'm on a brand team, I can get my
weekly and monthly reports,maybe even quarterly, on.
Here's the new RXs that werefilled in my region this week,
this month, this period.
Here's the refills that weredone.
But you but?
Is there other data insightsMedisafe is delivering back to
pharma teams that, frankly, theypreviously were invisible to in
regular models?
Speaker 2 (11:29):
It's incredible when you think about all of the data
that we are capturing literallyover 50 billion data points that
we're collecting on all ofthese patients globally we
really are able to give pharmainsights that they have never
seen before.
So we're not just tracking if adose was taken, we're actually
capturing why a dose might bemissed, or when engagement's
(11:52):
going to drop off and whatinterventions actually are
effective in re-engagingpatients.
So you know, for example, wecan see patterns like patients
tend to disengage around day 17if they've experienced certain
symptoms.
Well, that insight triggers ourJITI engine to preemptively
send targeted support at thatexact point in the patient's
(12:13):
journey.
And that's the kind ofbehavioral intelligence that is
just not available if you'relooking at claims data or
traditional hub reporting.
Speaker 1 (12:23):
So if I'm a patient listening to this, I might be a
little concerned about privacy.
How does Medisave handle myprivate data if we're sending it
to pharma companies?
Speaker 2 (12:31):
Well, privacy is paramount, and so we absolutely.
It is a consent-based situation.
Patients opt in to participatein the first place.
It's their data, they own theirdata.
We are HIPAA compliant, we areGDPR compliant, so we really
elevate and make sure that weare keeping patients' data
(12:52):
secure.
Speaker 1 (12:54):
And what surprised you the most.
In what patients are tellingyou about, you know what they
value the most in their digitalsupport tools.
Speaker 2 (13:01):
Oh, the biggest surprise.
Honestly, I think that patientsare more emotionally invested
than we really think, so weassume that they would want pure
utility.
But what we hear a lot is thatthis makes me feel seen, this
makes me feel heard.
We hear from patients regularly.
We have so many app storereviews where they're saying
(13:23):
MetaSafe really saved my life.
This is really bringingpatients through their ups and
downs and not just pushingalerts at them.
So you know, for example, we'vedone A-B testing and we've
shown that simple empatheticlanguage like we know it's hard,
and we've shown that simpleempathetic language, like we
know it's hard, but you've gotthis has improved engagement by
over 40% during challengingtherapy points.
(13:46):
So we're really addressing thiswhen they're facing the biggest
challenges.
And patients aren't justengaging with tech, they are
engaging with trust, and that'sshaped our design principles
going forward, and caregivers aswell, because sometimes they
can add a friend or somethingright.
Yeah, that friend very effective.
We've seen that that actuallyhas a huge contribution to
(14:08):
patient adherence, just knowingthat they've got someone walking
alongside them in that journey.
Speaker 1 (14:13):
All right.
So collaboration is often wherethe biggest digital health
challenges lie right.
So how does Medisave partnerwith pharma and life science
companies, versus just trying tosell a solution?
Speaker 2 (14:26):
Yeah, you know this goes back to we are not just a
vendor, we consider ourselvespharma's partner.
So in that way, what makes usdifferent is we are really
integrated within the pharmateams.
So we go and conduct pre-launchworkshops, we really align to
their launch objectives, wetrain the field so that across
(14:49):
commercial teams, across the ITand security cross-access teams
(15:09):
and with this we are ensuringthat there is internal alignment
and external adoption, becausedigital success comes from
really connecting that ecosystemand not just doing it in a silo
.
Speaker 1 (15:24):
Great.
And my last question, asdigital health rapidly is
evolving here and ever-changing,where do you see Medisafe
heading over the next two tothree years?
Speaker 2 (15:47):
So Medisafe over the next two to three years, that is
really we are adapting andreally doubling down on our AI
interventions.
We are really looking forwardto where can we layer this in
across multiple healthecosystems?
So we're advancing AIintegrations for predictive
adherence.
We are expanding into otherintegrations like EHR systems,
pharmacy services and thingslike that, and, of course, we're
global.
So we are global in every wayand we're making sure that we
(16:10):
are adaptive to all of the needs.
We have SDK modules that we'reable to integrate with.
So pharma, their needs arereally evolving I'd say rapidly
and they are being confrontedwith value-based care.
And how do they handle that?
What's a digital-firstintervention that's going to
work and really deliver on thatpatient ROI?
(16:31):
So we are ready Medisafe isready to scale across this with
handling and dealing with thecomplexities, while still
staying grounded in our roots ofempathy, evidence and
engagement.
Speaker 1 (16:47):
Thanks so much, kathy , for joining us today.
What you and the Medisave teamare really building represents
this new blueprint for howpharma and life sciences can
really move from justtransactions to trusted
relationships.
And you know, the real metricisn't just prescriptions written
, it's really prescriptionscompleted.
You know we're improving livesand you know we're moving
barriers and really helpingpeople on their journey.
(17:09):
So thank you so much forjoining us today.
On Postscripts A pleasure to behere, brian.
Thank you All.
Right, everyone.
If you found this conversationvaluable, follow or subscribe
for more insights at theintersection of pharma, tech and
patient impact.
Until next time, keep lookingforward.
The real work begins after thescript is written.
Have a good day everybody.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
My Favorite Murder with Karen Kilgariff and Georgia Hardstark
My Favorite Murder is a true crime comedy podcast hosted by Karen Kilgariff and Georgia Hardstark. Each week, Karen and Georgia share compelling true crimes and hometown stories from friends and listeners. Since MFM launched in January of 2016, Karen and Georgia have shared their lifelong interest in true crime and have covered stories of infamous serial killers like the Night Stalker, mysterious cold cases, captivating cults, incredible survivor stories and important events from history like the Tulsa race massacre of 1921. My Favorite Murder is part of the Exactly Right podcast network that provides a platform for bold, creative voices to bring to life provocative, entertaining and relatable stories for audiences everywhere. The Exactly Right roster of podcasts covers a variety of topics including historic true crime, comedic interviews and news, science, pop culture and more. Podcasts on the network include Buried Bones with Kate Winkler Dawson and Paul Holes, That's Messed Up: An SVU Podcast, This Podcast Will Kill You, Bananas and more.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.